Marshall Financial Group LLC Buys 441 Shares of ResMed Inc. (NYSE:RMD)

Marshall Financial Group LLC lifted its stake in ResMed Inc. (NYSE:RMD) by 4.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,472 shares of the medical equipment provider’s stock after acquiring an additional 441 shares during the quarter. Marshall Financial Group LLC’s holdings in ResMed were worth $2,074,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC acquired a new position in shares of ResMed during the 4th quarter worth approximately $27,000. Planned Solutions Inc. acquired a new position in ResMed during the fourth quarter worth $34,000. MV Capital Management Inc. raised its position in ResMed by 39.0% during the fourth quarter. MV Capital Management Inc. now owns 214 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 60 shares in the last quarter. Riverview Trust Co bought a new stake in ResMed during the first quarter worth $42,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in ResMed in the fourth quarter valued at $45,000. Institutional investors own 54.98% of the company’s stock.

Analyst Ratings Changes

RMD has been the topic of a number of research analyst reports. Citigroup cut shares of ResMed from a “buy” rating to a “neutral” rating in a report on Monday, June 24th. KeyCorp upped their price objective on ResMed from $227.00 to $238.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Oppenheimer downgraded ResMed from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 25th. Royal Bank of Canada increased their price target on ResMed from $187.00 to $200.00 and gave the company a “sector perform” rating in a research note on Friday, April 26th. Finally, Mizuho reaffirmed a “buy” rating and set a $215.00 price target on shares of ResMed in a report on Wednesday, March 27th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, ResMed has an average rating of “Moderate Buy” and an average target price of $202.80.

ResMed Stock Performance

ResMed stock traded up $0.05 during midday trading on Thursday, hitting $189.40. The company’s stock had a trading volume of 383,824 shares, compared to its average volume of 1,281,715. ResMed Inc. has a 1-year low of $132.24 and a 1-year high of $229.97. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.04 and a quick ratio of 1.97. The company has a 50-day moving average price of $208.82 and a two-hundred day moving average price of $191.63. The company has a market cap of $27.82 billion, a price-to-earnings ratio of 29.09, a PEG ratio of 1.64 and a beta of 0.66.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $2.13 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.22. ResMed had a net margin of 20.91% and a return on equity of 24.43%. The business had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the company earned $1.68 EPS. The business’s revenue was up 7.2% on a year-over-year basis. As a group, sell-side analysts predict that ResMed Inc. will post 7.7 earnings per share for the current year.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 13th. Shareholders of record on Thursday, May 9th were paid a $0.48 dividend. This represents a $1.92 annualized dividend and a yield of 1.01%. The ex-dividend date of this dividend was Wednesday, May 8th. ResMed’s dividend payout ratio (DPR) is 29.49%.

Insiders Place Their Bets

In other news, Director Witte Jan De sold 360 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $218.29, for a total value of $78,584.40. Following the completion of the transaction, the director now directly owns 7,519 shares in the company, valued at approximately $1,641,322.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Witte Jan De sold 360 shares of ResMed stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $218.29, for a total value of $78,584.40. Following the transaction, the director now owns 7,519 shares in the company, valued at approximately $1,641,322.51. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael J. Farrell sold 14,683 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $216.50, for a total value of $3,178,869.50. Following the sale, the chief executive officer now owns 440,752 shares of the company’s stock, valued at $95,422,808. The disclosure for this sale can be found here. Insiders sold 31,151 shares of company stock worth $6,666,409 in the last quarter. 1.21% of the stock is currently owned by corporate insiders.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.